{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019023","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.823365+00:00","generated_at":"2026-06-08T03:17:51.465731+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aytu Q1 FY2024: Adjusted EBITDA $2.2M (+32% YoY), ADHD revenue up 31%","bullets":["Net revenue $22.1M (down 20% YoY) due to Consumer Health wind-down; Rx segment $17.8M.","ADHD net revenue $15.1M, up 31% YoY; pediatric revenue $2.6M impacted by payor changes.","Net loss $8.1M ($1.48/sh) vs $0.7M loss last year; includes $5.9M loss on derivative warrant liabilities.","Adjusted EBITDA $2.2M vs $1.7M YoY; Rx segment Adjusted EBITDA $2.4M.","Cash $20.0M at Sept 30, 2023; FDA approvals for manufacturing site transfers for Adzenys and Cotempla."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019023","json":"https://secwatch.observer/filing/0001558370-23-019023.json","markdown":"https://secwatch.observer/filing/0001558370-23-019023.md","text":"https://secwatch.observer/filing/0001558370-23-019023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023019023/0001558370-23-019023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023019023/aytu-20231114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:17:51.465731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02a84d15335442501b280dd945422f309c6e2cba","claim":"AYTU BIOPHARMA, INC reported fiscal quarter ended September 30, 2023 results: revenue $22.1 million, net income Net loss during Q1 2024 was $8.1 million, or $1.48 per share, EPS $1.48 per share.","evidence_excerpt":"operational results for the first quarter of fiscal 2024 ended September 30, 2023. ​ Q1 2024 Commercial Highlights (3 months ending September 30, 2023) · Total net revenue was $22.1 million, compared to $27.7 million. The change is primarily due to the planned wind down of the Company’s Consumer Health segment and the associated decrease in Consumer Health revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023019023/0001558370-23-019023-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$22.1 million"},{"label":"Net income","value":"Net loss during Q1 2024 was $8.1 million, or $1.48 per share"},{"label":"EPS","value":"$1.48 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}